Polycystic Ovarian Syndrome Treatment Market

Market Overview

The global polycystic ovarian syndrome treatment market size was valued at USD 3.53 billion in 2022. It is estimated to reach USD 5.67 billion by 2031, growing at a CAGR of 5.61% during the forecast period (2023–2031). The availability of some medications on the market coupled with a significant increase in the number of unsatisfied demands for the treatment of PCOS is anticipated to create profitable chances for the expansion of the market.

PCOS, also known as polycystic ovary syndrome, is a hormonal disorder that impacts a sizeable portion of women of childbearing age. In addition to increased levels of male hormones, polycystic ovarian syndrome (PCOS) is probably to blame for irregular or unusually lengthy menstrual periods. PCOS is a condition that does not yet have a treatment that will reverse the condition; nevertheless, several medications can alleviate the symptoms and normalize the menstrual cycle. The market growth for treatments for polycystic ovarian syndrome may be linked to many major aspects.

The most important of these variables are an increase in the prevalence of PCOS, an increase in the knowledge of the patient population, and an increase in the use of combination therapy. Advancements in technologies for screening for PCOS, an increase in the demand for PCOS medications, and an increase in the availability of PCOS therapy additionally impact the expansion of the market. On the other hand, it is anticipated that the lack of approved therapies for PCOS and the lack of understanding regarding PCOS's pathophysiology and ethology will operate as a barrier to the establishment of the sector. It is because neither of these issues has been well addressed.

Market Dynamics

Global Polycystic Ovarian Syndrome Treatment Market Drivers

Rise in Prevalence of PCOS

The hormonal condition known as PCOS affects a significant percentage of women of childbearing age. It is anticipated that the growing incidence of PCOS will increase the demand for drugs that treat PCOS. For example, the Centers for Disease Control and Prevention (CDC) determined that polycystic ovary syndrome (PCOS) is one of the most common causes of female infertility. PCOS affects 6 and 12% (as many as 5 million) of American women of reproductive age.

The rising prevalence of co-morbid illnesses, including diabetes and obesity, contributes to an increase in the number of people diagnosed with polycystic ovary syndrome (PCOS). It is estimated that between 50 and 65 percent of women with PCOS are overweight or obese. As a result, the prevalence of polycystic ovarian syndrome will likely fuel the need for treatment medications, which is anticipated to drive market expansion.

Surge in Number of Pipeline Drugs

Many pharmaceutical companies have been motivated to research and develop new treatments due to the increasing frequency of PCOS illness. At the moment, several pharmaceutical companies are working on the creation of new pharmaceuticals for the treatment of polycystic ovary syndrome (PCOS), and a variety of PCOS medicinal treatments are currently in the process of being developed at various stages.

In addition, many companies are currently working on creating diagnostic tests that are accurate and conclusive in the hopes that they will assist in the early detection of this ailment. AZD4901, LIK066, and MSJ-0011 are examples of possible medications that are now in the development stage. As a result, the availability of some medications on the market coupled with a significant increase in the number of unsatisfied demands for the treatment of PCOS is anticipated to create profitable chances for the expansion of the market.

Global Polycystic Ovarian Syndrome Treatment Market Restraint

Lack of Approved Therapeutics for the Treatment of PCOS

Currently, there is no treatment or cure for polycystic ovary syndrome (PCOS), and the majority of the market is driven by treating problems associated with PCOS using a wide array of drugs that are not authorized for use in PCOS. There is not even a single drug that can be acquired without a prescription capable of addressing all of the problems connected with PCOS. These problems include the inability to have children, infertility, and irregular or absent periods. Consequently, the inaccessibility of licensed treatments and the usage of pharmacological applications that have not been approved are anticipated to impede the market's growth.

Global Polycystic Ovarian Syndrome Treatment Market Opportunities

Growth Opportunities in Emerging Markets

It is projected that prospects in developing economies that have not yet been explored would drive the expansion of the market for treatments for polycystic ovarian syndrome. It is anticipated that the availability of improved healthcare infrastructure, unmet demands in the healthcare industry, an increase in the prevalence of PCOS, and an increase in the demand for medications will be the primary drivers of these possibilities. A huge rise in the demand for better healthcare services and significant investments by governments to upgrade healthcare infrastructure are driving major growth in the healthcare business in emerging nations. The globalization of the healthcare industry is driving this growth. These emerging nations are experiencing this growth at a considerable and rapid rate.

Additionally, developing countries like China, India, and Brazil each have a sizeable patient population, which is a component that contributes to the escalation of this market. This aspect is one of the contributors to the growth of this market. During the period covered by this projection, each of these variables will create a lucrative opportunity for market growth.

Regional Analysis

Based on region, the global polycystic ovarian syndrome treatment market is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant global polycystic ovarian syndrome treatment market shareholder and is estimated to exhibit a CAGR of 3.8% over the forecast period. North America accounted for the largest share of the global market for treating polycystic ovarian syndrome (PCOS). It is expected to grow due to the region's higher prevalence of PCOS, healthcare awareness, a well-developed healthcare infrastructure, early disease detection, qualified medical professionals, and ease of access to therapeutics. According to the Centers for Disease Control and Prevention, PCOS affects 6 to 12% (up to 5 million) of American women of reproductive age, making it one of the most prevalent causes of female infertility. PCOS is caused by other variables like an unhealthy lifestyle, eating junk food, and a passive pattern of behavior, which boosts the market in North America.

North America's market for treating polycystic ovarian syndrome had a 47.37% share. The availability of cutting-edge healthcare facilities, the wide availability of PCOS treatment therapeutics, the rise in demand for these services with higher healthcare costs, and numerous hospitals and diagnostic centers with cutting-edge healthcare systems all contribute to the market's ongoing growth in this region.

Asia-Pacific is anticipated to exhibit a CAGR of 6.3% over the forecast period. Asia-Pacific presents numerous attractive chances for participants in the polycystic ovarian syndrome treatment market, and it is projected that it will record the highest growth rate throughout the forecast, as mentioned above period. This region's high population base, growth in the prevalence of polycystic ovarian syndrome treatment systems, and increase in demand for PCOS medicines all contribute to the market growth in this region. Countries in the Asia-Pacific region still in economic development are called emerging economies.

Additionally, several factors primarily drive the growth of the market, the most important of which is an increase in the number of people who fall into the target demographic, an increase in the number of hospitals and diagnostic centers that are equipped with cutting-edge medical technology, and an improvement in the general level of health awareness. Emerging economies are also responsible for a rise in the total population.

In European nations, the market for treating polycystic ovarian syndrome is anticipated to expand steadily throughout the forecast period. The main growth drivers in Europe are the rise in PCOS prevalence, the rise in demand for PCOS treatments, and the accessibility of PCOS treatments. Additionally, a developed healthcare infrastructure, the availability of experts with the necessary training, a higher prevalence of PCOS, and increased healthcare spending fuel the market's expansion in Europe. According to the National Health Service, about 1 in 5 women in the UK are said to have PCOS.

Moreover, due to increased PCOS therapeutic acceptance, increased hospitals and diagnostic facilities with skilled medical staff capable of early PCOS identification, and a rise in PCOS therapeutic centers, the European market is a significant stakeholder in the worldwide polycystic ovarian syndrome treatment market. The market for treating polycystic ovarian syndrome is expected to expand significantly in Germany, France, and the UK due to the high prevalence of the target population, the presence of a well-developed healthcare system, and the accessibility of pharmaceuticals.

In LAMEA, due to a lack of advanced healthcare facilities and a shortage of educated medical experts, the polycystic ovarian syndrome treatment market is still in its infancy. LAMEA is a developing market that presents lucrative growth possibilities for market players. This is because there is an increase in the target population, an increase in the number of hospitals, an improvement in healthcare infrastructure, and an increase in awareness toward the treatment of polycystic ovarian syndrome.

Segmental Analysis

The global polycystic ovarian syndrome treatment market is bifurcated into drug class and distribution channels.

Based on the drug class, the global polycystic ovarian syndrome treatment market is bifurcated into insulin-sensitizing agents, oral contraceptives, antiandrogens, anti-obesity drugs, and others. 

The insulin-sensitizing agent segment dominates the global market and is projected to exhibit a CAGR of 4.3% over the forecast period. In PCOS-affected women, insulin-sensitizing medications such as metformin, pioglitazone, and rosiglitazone are common since PCOS leads to impaired insulin sensitivity due to increased body weight. When treating obesity or weight loss in PCOS-affected women, metformin is preferred as the first-line treatment. Since these medications aid in the body's ability to respond to insulin and regulate glucose levels, the insulin-sensitizing agent's sector is the one that contributes the most to the market's overall revenue. Metformin and pioglitazone are effective at lowering elevated insulin levels and insulin resistance, which are frequently seen in PCOS patients.

Additionally, these medications aid in lowering high testosterone levels, acne, excessive hair growth, scalp hair loss, and high cholesterol levels, and they facilitate weight loss more easily. All of the variables mentioned above also influence the growth of this market segment.

Based on the distribution channel, the global polycystic ovarian syndrome treatment market is segmented into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

The drug stores and retail pharmacies segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 4.0% over the forecast period. A drug store, often known as a retail pharmacy, is a specific kind that deals in the distribution and retail sale of a wide range of therapeutic goods. In addition, pharmacies may also sell cosmetics, first-aid supplies, unique therapies, and pharmaceuticals that are available over the counter and do not require a prescription from a doctor. In addition, retail pharmacists provide patients with advice on the correct use of over-the-counter (OTC) medications and information regarding patients' overall health.

Currently, the market's principal source of revenue is being generated by retail pharmacies and other types of pharmacy stores. As a result of the broad availability of retail pharmacies worldwide and the ease of use that they offer, it is anticipated that this pattern will carry on during the period covered by the forecast.

Recent Developments

• January 2022- Celmatix Inc., a biotechnology company focused on ovarian biology, reported that a third milestone had been achieved in its five-year, multi-target alliance with Evotec. Evotec and Bayer AG triggered the milestone of advancing a PCOS drug program centered around a novel Celmatix-identified drug target into hit identification.
• June 2022- Bayer announced the launch of its brand-new Research and Innovation Center at Kendall Square in the United States, increasing the company's presence in one of the most cutting-edge centers for pharmaceutical research and development.